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The phospholipid analogue miltefosine or hexadecylphosphocholine (HePC) is a drug of high interest in the treatment for fatal visceral
leishmaniasis (VL) due to Leishmania donovani particularly because of its activity by oral route. In this study, the interaction of HePC with a
monolayer of h-palmitoyl-g-oleyl-phosphatidylcholine (POPC) as membrane model or sterol (ergosterol or cholesterol) was investigated. At
a constant pressure of 25 mN/m, the adsorption kinetics of HePC into the monolayers showed that HePC molecules are inserted into the
monolayer of lipids as monomers until the critical micellar concentration (CMC). At HePC concentrations superior to the CMC, the micelles
of HePC are deployed at the interface as groups of monomers into the POPC or sterol monolayer. The study of mixture of HePC/(POPC or
sterol), spread at the air–water interface, shows that a simple miscibility between HePC and POPC is observed, whereas a high condensation
appears between HePC and sterols showing a high affinity between HePC and sterols. In addition, HePC does not act as detergent disturbing
membrane integrity.
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Leishmaniases are parasitic diseases due to Leishmania, a
dimorphic protozoan that exists as flagellated mobile pro-
mastigotes in sandfly vector and as intracellular amastigote
in the mammalian host. Leishmaniases are considered by the
World Health Organization to be one of the six major
diseases in developing countries [1].
Several species of Leishmania are responsible for at least
three major forms of infections in man: cutaneous, mucosal
and visceral leishmaniasis (VL).
VL infection, particularly due to species of Leishmania
donovani, is the most damaging form because fatal if
untreated. There are annually nearly 0.5 million new cases
of VL [2]. Along with Brazil, Bangladesh and Sudan, India0005-2736/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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VL presents as fever, hepatosplenomegaly and pancytopenia.
Chemotherapy is the only real means to control this
disease since vaccine or vector eradication is still hypothet-
ical. However, chemotherapy has to be improved to over-
come the problems of resistance, toxicity and high cost of
available drugs. The two pentavalent antimonial compounds,
sodium stibogluconate and meglumine antimoniate, admin-
istered parenterally as first line chemotherapeutic agents
against all forms of leishmaniasis including VL are toxic
and widespread resistance is reported mainly in India, Kenya
and Sudan [4–7]. In case of antimonial resistance, Ampho-
tericin B (AmB) which binds to membrane sterols [8,9] is
used as liposomal formulation (AmBisomeR) administered
intravenously despite its nephrotoxicity [10–12]. Other lipid
formulations of AmB exist and are also administered intra-
venously [13,14]. The major limitation that prevents more
widespread use of these formulations is their high cost.
Therefore, it is useful to define low-dose treatment regimens,
but they remain too expensive for most endemic countries
[15,16].
The phospholipid analogue miltefosine or hexadecyl-
phosphocholine (HePC) (Fig. 1) acquires growing interest
Fig. 1. Chemical structure of HePC.
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activity by oral route.
HePC was primarily developed as antitumoral agent,
particularly for the treatment of cutaneous metastases
from breast cancers [17,18]. HePC is clinically efficient
in India as oral drug for the treatment of VL. Recent
study showed that 94–97% of patients treated orally and
daily with miltefosine at approximately 2.5 mg per
kilogram of body weight for 28 days were cured and
had no relapse after 6 months [19]. Moreover, HePC
remains hopeful even for immunodeficient patients with
VL [20] and it is also efficient for cutaneous leishman-
iasis [21]. However, the mechanism of action of HePC is
still unknown.
The uptake of HePC, a water-soluble amphiphilic mol-
ecule in eukaryotic cells, may be done by passive diffusion,
by the means of a transporter or by endocytosis [22]. We
hypothesize that HePC, because of its chemical structure,
could have a direct interaction with the cell membrane. In
order to assess this assumption, we propose therefore to
analyze the physico-chemical interaction between HePC and
a phospholipid or a sterol monolayer, a simplified external
membrane model.2. Materials and methods
2.1. Reagents
Miltefosine or hexadecylphosphocholine (HePC) (Fig.
1), an amphiphilic molecule, was kindly provided by
Zentaris (Frankfurt, Germany). Solutions of HePC were
daily prepared in distilled water (Millipore) or in chloro-
form/ethanol 1:1 (v/v) at initial concentration of 10 3 M.
These solutions were immediately used for measurements.
Chloroform and ethanol were purchased from Sigma (St.
Louis, MO, USA) and were 99% pure and used without
further purification.
2.1.1. Lipids
h-Palmitoyl-g-oleoyl-phosphatidylcholine (POPC, a
zwitterionic phospholipid) was chosen for three major
reasons: first, because it is an amphiphilic molecule which
can spread at the air–water interface and form stable
monolayer; second, because of its oleic and palmitic chains
and phosphocholine polar head group are major components
in biological membranes in eukaryotic cells; third, the mean
transition temperature of POPC (Tm= 3 jC) is close to
that of biological membranes phospholipids.Plasma membranes of eukaryotic cells contain, in addi-
tion to phospholipids, varying amounts of sterol. Ergosterol
was chosen because it is the major sterol component in
addition to cholesterol in Leishmania sp. [9,23].
POPC, cholesterol and ergosterol were purchased from
Sigma and were 99% pure and used without further purifi-
cation. For the surface pressure measurements, POPC,
cholesterol and ergosterol were dissolved in a chloroform/
ethanol 1:1 (v/v) mixture at a concentration of 10 3 M.
2.2. Monolayer study
Monolayers were prepared as already described [24] by
using a Teflon trough provided by Riegler (Riegler and
Kirstein GmbH, Wiesbaden, Germany). The trough (6.2
26.3 0.5 cm) was filled with NaCl solution (150 mM,
pH = 5.6) or pure water (pH = 5.6). The surface pressure was
measured with the Wilhelmy method, by means of a thin
plate of filter paper. An electronic device enabled us to keep
the surface pressure constant by monitoring the displacement
of the barriers. This system was used during adsorption
experiments. All experiments were performed at 21F1
jC. The speed of compression and decompression of the
barriers (3 10 2 cm s 1) was kept constant during the
experiments.
2.2.1. HePC adsorption at the interface and critical
micellar concentration (CMC) determination
HePC was injected at a final concentration in the range
from 0.2 to 5 AM into the trough. According to the
Wilhelmy plate techniques, we studied the adsorption of
HePC at the air–water interface at a constant surface area of
45 cm2. The variation of surface pressure as a function of
time was recorded. The reached maximum surface pressure
(Pmax) was reported as a function of HePC concentrations in
order to determine the CMC of HePC.
2.2.2. HePC interaction with lipids (POPC or sterols)
Two techniques were employed to study the POPC/HePC
or sterol/HePC interactions.
2.2.2.1. Adsorption of HePC solutions in the presence of a
lipid monolayer. A lipid monolayer was obtained by
spreading 20 Al of POPC or sterol at initial concentration
of 10 3 M at the interface. Then, this monomolecular film
was compressed until 25 mN/m. Generally, the surface
pressure of biological membrane is estimated at 30 mN/m,
but reliable measurements must be done at 25 mN/m,
pressure not close to the collapse pressure of HePC
(Section 3.1.2).
(i) In the first case, the surface pressure (P) was kept
constant (25 mN/m) and an aqueous solution of HePC was
injected with a microsyringe under the monolayer at a final
concentration in the range from 0.2 to 4 AM, according to
the process described previously [25]. If an interaction
occurred between the molecules of the subphase and the
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25 mN/m and the variation of the mean molecular area of
lipid versus time was recorded during 60 min (adsorption
kinetics). The maximal percentage of HePC monomers
(%HePCmax) inserted into the lipid monolayer is calculated
from the following formula [26]
%HePCmax ¼ ðDA=AHePCÞ=ð1þ DA=AHePCÞ ð1Þ
DA is the variation of the area per molecule of lipid at the
constant surface pressure and AHePC, the cross section of
HePC, determined by HePC compression isotherms (Sec-
tion 3.1.2).
(ii) In the second case, the surface of trough (cor-
responding to a surface pressure of 25mN/m)was maintained
constant. An aqueous solution of HePC was injected under
the monolayer at a final concentration in the range from 0.2 to
4 AM. The variation of surface pressure DP of lipid in the
presence of HePC was recorded during 60 min.
2.2.2.2. Spreading of mixed lipids: HePC/POPC or
sterol. Mixed HePC/lipid organic solutions were prepared
in ethanol/chloroform 1:1 (v/v) with various ratios. Twenty
microliters of each mixture was spread using a microsyringe
at the air–water interface. The mixed films were com-
pressed in order to obtain an isotherm pattern. At a constant
surface pressure of 25 mN/m, a phase diagram was obtained
by reporting the measured mean molecular area as a
function of the HePC molar fraction. The theoretical mo-
lecular area obtained if no interaction is assumed between
HePC and lipids (additivity curve) was obtained by joining
the points corresponding to the molecular area of the lipid
alone and the molecular area of HePC alone. If the resulting
curve is linear, there is a simple additivity between HePC
and the lipid; a concave curve indicates a condensation and,
on the contrary, a convex one indicates an extension.Fig. 2. Determination of HePC CMC: maximal surface pressure obtained
from adsorption of HePC at constant area (45 cm2) versus HePC
concentration; (o) distilled water, (n) NaCl concentration: 150 mM.
Subphase: pH= 5.6, T= 21F1 jC.3. Results
3.1. Behavior of HePC alone at the air–water interface
3.1.1. HePC adsorption at the interface and CMC
measurements
HePC is composed of two parts, an hydrophobic chain of
16 carbons and a polar head group of PC, which confers it
tensioactive properties. This amphiphilic molecule is soluble
in water but can form monolayer at the air–water interface.
In order to know the state of active HePC against parasites,
under the form of monomers or aggregates, we first have to
determine the CMC of HePC.
An HePC aqueous solution was injected into the sub-
phase of the Langmuir trough. At low concentrations below
the CMC, HePC was essentially soluble in water in the form
of monomers. As HePC is an amphiphilic molecule, mono-
mers are able to adsorb at the interface. At concentrationssuperior to the CMC, there was micelle formation in the
trough and saturation of adsorbed monomers at the interface
occurred. The maximum surface pressure (Pmax) was
reported as a function of HePC concentrations (Fig. 2) in
order to determine the CMC of HePC. The plateau corre-
sponds to the saturation of the surface by the monomers of
HePC. The CMC was estimated in the range from 2 to 2.5
AM in the presence of 150 mM NaCl into the subphase and
in the range from 2.5 to 3 AM in the presence of distilled
water.
3.1.2. HePC compression isotherms
Because of its intermediate solubility, it is possible to
dissolve HePC in water as well as in organic solvent.
Isotherms of HePC were recorded in three different cases
and compared. Either 20 Al HePC dissolved in chloroform/
EtOH 1:1 (v/v) or in distilled water at initial concentration
of 10 3 M was spread at the air–water interface, or 20
Al HePC aqueous solution corresponding to a HePC final
concentration of 0.2 AM<CMC was injected in the trough.
The isotherms recorded 60 min after spreading and
adsorption of HePC from aqueous solution are represented
in Fig. 3 (curves a and b). The obtained low mean molecular
area shows that a part of HePC molecules are dissolved in
the subphase. On the contrary, the compression isotherms
obtained from an organic solution performed 10 min and 1
h after spreading (Fig. 3, curves c and d) are close,
indicating that all molecules stay at the interface. Thus,
the maximum pressure (collapse) reached in isotherms of
HePC was found at 35 mN/m and the minimum molecular
area reached was found at 26 A˚2. This value is close to the
Fig. 4. Variation of the molecular area (DA) of POPC (a) and ergosterol (b)
as a function of HePC concentration injected at constant surface pressure
P= 25 mN/m, from an aqueous solution under the monolayer. (.)
Monomers; (n) micelles and monomers. Subphase: distilled water,
pH = 5.6, T= 21F1 jC.
Fig. 3. HePC isotherms recorded: 1 h after injection from an aqueous
solution into the trough (curve a), 1 h after spreading from an aqueous
solution at the interface (curve b), after spreading from an organic solution
at the interface, after 10 min (curve c) and after 1 h (curve d). Subphase:
distilled water, pH = 5.6, T= 21F1 jC.
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further calculations the cross section of the HePC molecule
(AHePC) will be estimated at 26 A˚
2.
3.2. Interaction of HePC with monolayer of lipid (POPC or
sterols)
3.2.1. At constant surface pressure
A lipid monolayer (POPC or sterol) was spread at the
interface and compressed until 25 mN/m.
In the first case, this surface pressure (P) was kept
constant and an aqueous solution of HePC was injected
under the POPC monolayer according to the process de-
scribed in Section 2.2.2.1. The variation of the mean
molecular area (DA) of POPC and of ergosterol versus
HePC concentration is reported in Fig. 4a and b. The same
results are obtained with cholesterol (data not shown). In the
two cases, we note that until 2 AM, close to the CMC value
(2.5 AM), the area per molecule of POPC increases pro-
gressively due to an insertion of HePC monomers into the
lipid monolayer. These values are higher in the presence of
POPC (Fig. 4a) than sterol (Fig. 4b) because of the state of
these lipids: at 21 jC POPC is in liquid expanded (fluid)
phase, cholesterol and ergosterol in condensed (ordered)
phase. According to the formula (Eq. (1)), at 25 mN/m the
maximum percentage of HePC monomers inserted into a
POPC monolayer or into a sterol (ergosterol or cholesterol)
monolayer, calculated for 2 AM, reached about 28% and
16%, respectively. Above the CMC concentration, curves
are not only no linear but values may also considerably vary
for one same concentration of HePC. In fact, some micellesof HePC reached interface and were deployed as groups of
monomers into the POPC or sterol monolayer, creating an
abrupt anarchical increase of the molecular area. The
micelles in solution constitute a reserve of monomers for
the interface.
3.2.2. At constant molecular area
In the second case, the surface of trough corresponding to
a surface pressure of the lipid of 25 mN/m was maintained
constant and an aqueous solution of HePC was injected
under the monolayer. At this pressure the area per molecule
is 69F 0.5 A˚2 (Fig. 5) and 34F 0.1 A˚2 (Fig. 6), respectively
for POPC and ergosterol. Tables 1 and 2 report the varia-
tions of surface pressure (DP) versus HePC concentration in
Table 1
Variations of the surface pressure (DP) of POPC after adsorption of HePC
from an aqueous solution at constant molecular area of POPC (69F 0.5 A˚2)
HePC (AM) DP (F 0.5 mN/m)
Instantaneous After 1 h
0.5 2 2
1 3.5 7
1.5 5 9
2 5.2 10
2.5 8 10
3 8 12
4 8 12
Subphase: distilled water, pH = 5.6. T= 21F1 jC.
Fig. 5. Isotherm pattern of mixed films of HePC/POPC (mol/mol) at
different molar fractions. (E) HePC, (o) HePC/POPC 80:20, ( ) HePC/
POPC 40:60, (.) HePC/POPC 30:70, (5) HePC/POPC 20:80, (n) POPC.
Subphase: distilled water, pH = 5.6, T= 21F1 jC.
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instantaneously and 1 h after injection (the same results
are obtained with cholesterol). In the presence of POPC,
instantaneous DP values increase progressively from 2 to
8 mN/m, whereas in the presence of sterol (ergosterol or
cholesterol) these values immediately reach 6 mN/m even at
low HePC concentration. On the one hand, as ergosterol and
cholesterol are in a condensed state, a very few quantity of
adsorbed molecules carries an important variation of pres-
sure. On the other hand, these results can involve a higher
affinity of HePC for sterol than for POPC.
One hour after injection and above the CMC of HePC,
the maximum variation of surface pressure is 12 mN/m
(DPmax), both in the presence of POPC and sterol cor-
responding to the saturation of HePC molecules into the
monolayer. If we add to this value (12 mN/m) the initial
surface pressure of POPC or ergosterol (25 mN/m), we
obtain 37 mN/m close to the maximum pressure reached by
HePC alone (see Fig. 3 and Section 3.1). Beyond this
maximum cohesion pressure, HePC molecules cannot be
inserted any more into the lipid monolayer. These results
complete those obtained at constant surface pressure: HePC
molecules are inserted into the monolayer as monomers
until the maximum cohesion of HePC molecules at the
interface. The fact that the monolayer pressure did not
decrease show that POPC molecules remained at the inter-
face and were not solubilised by HePC micelles. So, HePC
does not act as a detergent able to destroy the membrane
integrity.Table 2
Variations of the surface pressure (DP) of ergosterol after adsorption of HePC
(aqueous solution) at constant molecular area of ergosterol (34F 0.5 A˚2)
HePC (AM) DP (F 0.5 mN/m)
Instantaneous After 1 h
0.5 6 6
1 6.5 9
1,5 6 9
2 6.5 10
2,5 6 10
3 6,5 12
4 9,5 12
Subphase: distilled water, pH = 5.6. T= 21F1 jC.3.3. Spreading of mixed lipids (POPC or sterol/HePC)
To study the relative affinity between lipid (POPC or
sterol) and HePC, mixed HePC/lipid organic solutions
prepared in ethanol/chloroform 1:1 (v/v) were spread at
the air–water interface. The mixed films were compressed
in order to obtain an isotherm pattern (Figs. 5 and 6). FromFig. 6. Isotherm pattern of mixed films of HePC/ergosterol (mol/mol) at
different molar fractions. (E) HePC, (o) HePC/ergosterol 90:10, (x)
HePC/ergosterol 80:20, ( ) HePC/ergosterol 60:40 (n) HePC/ergosterol
50:50, (D) HePC/ergosterol 40:60, (.) HePC/ergosterol 20:80, (5)
ergosterol. Subphase: distilled water, pH = 5.6. T= 21F1 jC.
Fig. 7. Phase diagram obtained from isotherms patterns at P= 25 mN/m.
(.) HePC/POPC; (n) HePC/ergosterol. The linear line represents the
additivity curve.
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(Fig. 7). When we compared the experimental mean mo-
lecular area at this pressure obtained for the different
mixtures of HePC/POPC (mol/mol) with the theoretical
additivity curve (linear curve), we observed that almost all
experimental points are close to this line. This means that
there is only a simple additivity between POPC and HePC
molecules. These results complete those obtained with the
adsorption technique (Section 3.2), which underscore a
simple insertion of HePC monomers into the POPC mono-
layer. We can expect also that HePC and POPC are miscible,
first, because we do not observe the collapse of HePC,
which occurs at 35 mN/m, on the other HePC/POPC
isotherms; second, due to the fact that the structures of
these molecules are close.
Concerning the mixtures of HePC/ergosterol, we ob-
served that all experimental points are under the additivity
curve, indicating an attraction between sterol and HePC.
The maximum of condensation is reached at a ratio of
HePC/POPC 50:50 (mol/mol). Since sterols are rigid and
incompressible molecules, a condensation of HePC with
ergosterol occurs, indicating a high affinity between HePC
and ergosterol. The same results were obtained with cho-
lesterol (data not shown). This behavior connects with the
condensing effect of cholesterol towards phospholipids in
general [27–29].4. Discussion
We have first determined the CMC of HePC to know
whether HePC acts as monomers or micelles. The CMC of
HePC was estimated at about 2.5 AM in distilled water. This
value is fourfold lower than those found by Soares de
Araujo et al. [30]. However, this result was obtained under
different conditions using 50 mM sodium acetate buffer.The presence of NaCl solution into the subphase has no
significant influence on HePC adsorption as we found a
similar CMC in distilled water and in 150 mM NaCl [30].
However, our results obtained with lipid monolayers
showed that HePC molecules insert into the monolayer as
monomers and that some micelles of HePC reaching inter-
face were deployed as groups of monomers into the POPC
or sterol monolayer. It can be assumed that HePC insert into
the Leishmania plasma membrane as monomers and that
micelles create a local disorder in the external membrane
layer by deployment as monomers. The micelles in solution
constitute a reservoir of monomers for the interface. In the
research for potential molecular targets of HePC, it was
shown that HePC inhibits the specific acyl-CoA acyltrans-
ferase enzyme and this inhibition is dose-dependent with an
inhibitory concentration of 50 AM up to the CMC of HePC
[31]. So we suggest that for its biological activity, HePC
must be in concentration above the CMC.
Cell membranes of higher organisms contain in addition
to phospholipids varying amounts of cholesterol. The two
lipids differ in their swelling properties [32] and their
association results in a condensed state [27]. In addition to
cholesterol, the major sterol found in the protozoan Leish-
mania plasma membrane is ergosterol [9]. Our biophysical
results showed that HePC has a high affinity for sterols and
that no selectivity occurs between ergosterol and cholester-
ol. In addition, we found that HePC, despite its chemical
structure, does not act as detergent disturbing the membrane
integrity. Finally, we suggest that HePC inserts into the
membrane phospholipid by miscibility and interacts with
sterols of the membrane.Acknowledgements
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